

Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant

NCT03354728

Status	RECRUITING
Phase	Phase 1, Phase 2
Sponsor	City of Hope Medical Center
Enrollment	80 participants

Key Eligibility Criteria

Inclusion (9)

- All subjects (or their guardians) must have the ability to understand and the willingness to sign a written informed consent; age appropriate assent will be obtained per institutional guidelines; to allow non-English patients to participate in this study, bilingual health services will be provided in the appropriate language when feasible
- Participant must be willing to comply with study and/or follow-up procedures, including willingness to be followed for one year post-HCT
- Planned allogenic (allo)-HCT, with 9/10 or 10/10 (A, B, C, DRB1, DQB1) high/intermediate resolution HLA donor allele matching and with no T-cell depletion of graft
- Planned related HCT with molecular 3/6 HLA donor allele matching (haploidentical) (for phase I only)
- CMV seropositive at the time of HCT
- ... and 4 more (see full listing online)

Exclusion (16)

- TRANSPLANT RELATED CRITERIA: Patients undergoing cord blood transplant (CB-HCT)
- Any prior investigational CMV vaccine
- Anti-CMV therapy in the last 6 months
- Live attenuated vaccines
- Medically indicated subunit (Engerix-B for HBV; Gardasil for human papillomavirus \[HPV\]) or killed vaccine (e.g. influenza, pneumococcal)
- ... and 11 more (see full listing online)

Locations (1 total)

City of Hope Medical Center, Duarte, California, United States

<https://clinicaltrials.gov/study/NCT03354728>

DISCLAIMER: This document is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before enrolling in any clinical trial. Information may not be up to date — verify details at [ClinicalTrials.gov](https://clinicaltrials.gov). Generated by [ClinicalTrialsFinder.org](https://clinicaltrialsfinder.org).